Sharing attention with the ACAAI annual meeting and the start of viral respiratory season, this month’s issue of the Annals of Allergy, Asthma and Immunology focuses on primary immune deficiencies (PID) with some very helpful articles. The CME review focuses on PID that are associated with elevated IgE. One of the key features in these patients is cutaneous viral infections along with eczema. This review has a very helpful figure to help your diagnosis and management of these patients. Another review focuses on specific antibody deficiency with associated poor response to polysaccharide antigens, including key insights to vaccine responses. The final review addresses the ongoing issue of COVID-19 vaccination in patients with primary immune deficiency – showing both safety and efficacy in this population.
The Marginal Zone cartoon continues with the theme of PID treatment by exploring the history of IgG replacement therapy in a lighthearted fashion. An accompanying perspective gives key insights into the management of immunoglobulin replacement.
Issues of Annals include clinical trials in order to bring the latest clinical results that affect our patients to you. The research articles in this month’s issue focus on two recent clinical trials that impact our patients and their care. One study examines the use of patient-reported outcomes (PROs) with the use of tralokinumab in the treatment of atopic dermatitis, showing clinical improvement in itch and quality of life. The other clinical trial examines the use of combination olopatadine and mometasone in the treatment of allergic rhinitis, demonstrating improvement in symptoms compared to a placebo spray. These studies highlight potential new therapies that exist – or may exist in the future – for the treatment of our patients.
As in every month’s issue there are many more insightful and impactful original research articles, as well as short communications, such as letters to the editor, that will help you provide the best possible care to your patients. Indeed, studies in this month’s issue range from research into angioedema, anaphylaxis, and asthma to Prader-Willi, rhinitis, and tryptase.
And, as always, if you have any comments, please consider sending correspondence to Annals (email us at annals@ACAAI.org). I am always excited to hear how Annals has helped you improve the lives of your patients!
Jonathan Spergel, MD, PhD, FACAAI